Who are immunotherapy Staloral's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sublingual allergen extract, Pangramin SLIT HDM mix., Grazax-R, HDM SLIT-tablet, Slit One ragweed, SUBLIVAC FIX Birch.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/immunotherapy-staloral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

immunotherapy Staloral — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

immunotherapy Staloral (immunotherapy Staloral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sublingual immunotherapy (SLIT). Area: Immunology / Allergy.

marketed Sublingual immunotherapy (SLIT) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

immunotherapy Staloral (immunotherapy Staloral) — Medical University of Silesia. Staloral is a sublingual immunotherapy that desensitizes the immune system to allergens by inducing immune tolerance through repeated exposure to gradually increasing allergen doses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
immunotherapy Staloral TARGET	immunotherapy Staloral	Medical University of Silesia	marketed	Sublingual immunotherapy (SLIT)
sublingual allergen extract	sublingual allergen extract	Medical University of Lodz	marketed	Sublingual immunotherapy (SLIT)
Pangramin SLIT HDM mix.	Pangramin SLIT HDM mix.	ALK-Abelló A/S	phase 3	Sublingual immunotherapy (SLIT)
Grazax-R	Grazax-R	ALK-Abelló A/S	phase 3	Sublingual immunotherapy (SLIT)	Grass pollen allergen (timothy grass, Phleum pratense)
HDM SLIT-tablet	HDM SLIT-tablet	ALK-Abelló A/S	phase 3	Sublingual immunotherapy (SLIT) tablet
Slit One ragweed	Slit One ragweed	ASST Fatebenefratelli Sacco	phase 3	Sublingual immunotherapy (SLIT)	Ragweed allergen (Amb a 1 and related epitopes)
SUBLIVAC FIX Birch	SUBLIVAC FIX Birch	HAL Allergy	phase 3	Sublingual immunotherapy (SLIT)	Birch pollen allergens (Bet v 1 and related epitopes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sublingual immunotherapy (SLIT) class)

ALK-Abelló A/S · 2 drugs in this class
ASST Fatebenefratelli Sacco · 1 drug in this class
HAL Allergy · 1 drug in this class
Medical University of Lodz · 1 drug in this class
Medical University of Silesia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). immunotherapy Staloral — Competitive Intelligence Brief. https://druglandscape.com/ci/immunotherapy-staloral. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab